DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (Protocol # DELFI L-101) (NCT04825834)
The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.
Contact
Clinical Trials Office at [email protected] or (203) 358-8879.
Principal Investigator(s)
Michael Bernstein, MD
Sponsor(s)
DELFI Diagnostics, Inc.
Location
SHMG- Pulmonary Associates
29 Hospital Plaza
Stamford, CT 06902
Stamford, CT 06902